Abstract
This paper looks at the history, consequences and current situation with respect to marketing a generic omeprazole product in the EU. In 1997, Astra (now AstraZeneca) took the disruptive strategy of limiting or avoiding generics competition, by withdrawing their capsule reference product and replacing it with a tablet product prior to generics registration being approved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
